Prenetics Ltd Stock Price, News & Analysis

Prenetics Global Limited (NASDAQ: PRE) announced its fourth quarter and full year 2022 financial results, reporting a revenue of US$275.8 million for 2022 and US$52.3 million for Q4 2022, reflecting a 19.2% decrease year-over-year. The Company achieved an adjusted EBITDA of US$58.3 million for 2022. Notably, Prenetics is shifting focus to precision oncology, highlighted by the acquisition of ACT Genomics, the first Asian firm to receive FDA clearance for its genomic profiling test. The Company aims to implement a US$20 million share buy-back program while also reducing its workforce by 60% to streamline operations and cut costs.

Prenetics Global Limited (NASDAQ: PRE) has announced the formation of a new Scientific Advisory Board (SAB) aimed at enhancing its diagnostic cancer genomics platform. The SAB comprises respected experts in oncology and genomics, including Prof. Tony Mok, who will chair the board. This strategic move is designed to leverage their expertise for advancing precision oncology, particularly early cancer detection. CEO Danny Yeung emphasized the significance of these appointments in driving innovative solutions for cancer treatment. Prenetics continues to focus on its goal of transforming patient care through advanced genomic technologies.

Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to 16, 2023. Founded in 2014, Prenetics aims to decentralize healthcare by making consumer health, clinical care, and medical genomics accessible worldwide. The company operates in nine locations, including the UK, Hong Kong, and India, and offers services such as genetic testing, colorectal cancer screening, and COVID-19 testing. The event underscores Prenetics' commitment to innovation in health and diagnostics.

F.N.B. Corporation (NYSE: FNB) has declared a quarterly cash dividend of $18.13 per share on its Non-Cumulative Perpetual Preferred Stock, Series E (NYSE: FNB.PRE). This dividend is equivalent to $0.45325 per depositary share. The payment will be made on February 15, 2023, to shareholders recorded as of January 31, 2023. With total assets nearing $43 billion and approximately 340 banking offices, FNB operates in several states and D.C., offering comprehensive commercial and consumer banking solutions.

Prenetics Global Limited (NASDAQ: PRE) announced a leadership change with Dr. Bayju Thakar appointed as CEO of Prenetics EMEA, effective immediately. This strategic move is aimed at enhancing the company’s growth in the complex EMEA healthcare market. Dr. Thakar, former CEO of Doctor Care Anywhere, brings over 20 years of healthcare experience and a strong digital health background. With an emphasis on expanding into primary care, IVF, and personalized cancer diagnostics, Prenetics seeks to leverage its robust balance sheet for both organic and inorganic growth opportunities across the region.